

14/09/2009

Antisoma's preliminary results for the year ended 30 June 2009

London, UK, and Cambridge, MA: 14 September 2009 Antisoma plc (LSE: ASM; USOTC: ATSMY) today announces its preliminary results for the year ended 30 June 2009. These results have been prepared under International Financial Reporting Standards ('IFRS') as adopted for use by the European Union.

Highlights of 2008/2009

ASA404 programme advances and expands

Strong partnership maintained with Novartis

Phase III trial in first-line lung cancer completes enrolment of 1200 patients (September 2009)

Phase III trial in second-line lung cancer initiated

Breast cancer selected as next indication for development

AS1413 development gains momentum

Phase III trial in secondary AML expanded

Phase II trial shows durable responses in secondary AML

AS1411 programme advances

Positive data from phase II trial in AML

Plans announced for phase IIb development in AML

Phase II trial in renal cancer completes patient enrolment

Value realised from oral fludarabine asset

Drug approved by FDA

Divested to sanofi-aventis in USD 65 million deal

Strong cash position

Oral fludarabine divestment extends cash runway to mid-2011

Cash life now extends beyond expected timing of key phase III data

Cash and short-term deposits of GBP 67.0 million at 30 June 2009

Full-year loss of GBP 16.4 million

Commenting on the results, Glyn Edwards, CEO of Antisoma, said: "We have made important progress this year, with gathering momentum on our two phase III programmes, positive phase II data for a third product and our first product approval from the FDA. With the pipeline maturing, we now have a dual focus on driving products towards regulatory approvals and on building a strong platform for product commercialisation."

Eric Dodd, Antisoma's CFO, added: "The successful divestment of oral fludarabine to sanofi-aventis has added significantly to our cash resources, further strengthening our balance sheet. We can now fund all our priority programmes until mid-2011, beyond the time we expect key phase III data for ASA404 and AS1413."

A webcast and conference call will be held today at 9:30 am BST. The webcast can be accessed via Antisoma's website at <http://www.antisoma.com/asm/media/webcast/> and the call by dialling +44 (0) 207 806 1964 UK Toll (US Toll +1 718 354 1390) and using the Confirmation Code: 9656482. A recording of the webcast will also be available afterwards on the Antisoma website.

Enquiries:

Antisoma plc

+44 (0)7909 915 068

Glyn Edwards, *Chief Executive Officer*

Daniel Elger, VP, Marketing & Communications

Buchanan Communications
(All media enquiries)
Mark Court, Lisa Baderoon

+44 (0)20 7466 5000

The Trout Group
(US investor enquiries)
Seth Lewis

+1 617 583 1308

Except for the historical information presented, certain matters discussed in this statement are forward looking statements that are subject to a number of risks and uncertainties that could cause actual results to differ materially from results, performance or achievements expressed or implied by such statements. These risks and uncertainties may be associated with product discovery and development, including statements regarding the Group's clinical development programmes, the expected timing of clinical trials and regulatory filings. Such statements are based on management's current expectations, but actual results may differ materially.

[View the preliminary results in PDF format \(69 KB, opens a new browser window\)](#)



This page includes links to documents in Portable Document File (PDF) format. To read PDF documents you may need to download the free [Adobe Acrobat Reader](#). For PDF accessibility help, visit [Access Adobe](#). These links will open in a new browser window.

[^ Back to top](#)

[centre](#) | [Media centre](#) | [Partnering](#) | [Careers](#) | [Contact us](#) | [Site map](#) | [Alert service](#) | [Disclaimer](#) | [Accessibility](#)